Mar 4 2010
Corning Incorporated (NYSE:GLW) today introduced the Corning® Synthemax™ 
      surface, a novel synthetic surface that supports the growth and 
      differentiation of stem cells. The surface is being commercialized as a 
      result of Corning’s ongoing collaboration with Geron Corporation 
      (NASDAQ:GERN). This development enables researchers to take the next 
      step toward scalable and cost-effective manufacturing of stem cells for 
      potential therapies in the treatment of degenerative diseases.
    
“The commercialization of the Synthemax surface is a clear proof point 
      of the success of our collaboration with Geron”
    
      Data presented by Corning and Geron at the World 
      Stem Cell Summit in Baltimore in September 2009 demonstrated 
      multi-passage growth of multiple undifferentiated human stem cell lines 
      and the subsequent differentiation of one of these cell lines into 
      cardiomyocytes. This is the first time the differentiation has been 
      demonstrated with the results presented on a synthetic surface. The 
      growth and differentiation of stem cells on the Synthemax surface is 
      robust and reproducible, an important condition for the large-scale 
      production of cells and therapeutic development.
    
    
      “The commercialization of the Synthemax surface is a clear proof point 
      of the success of our collaboration with Geron,” said Dr. 
      Jeff Mooney, director of commercial technology for Corning 
      Life Sciences. “By leveraging our unique expertise in materials and 
      surfaces, as well as Geron’s advanced therapeutic stem cell techniques, 
      we have been able to develop what we believe is the first and only 
      synthetic surface in the world to enable this level of stem cell growth 
      and differentiation.”
    
    
      The Corning Synthemax surface allows for the scalable expansion of stem 
      cells for more than 20 serial passages in a defined xeno-free medium 
      with:
    
    
      - 
        Stable doubling time;
      
- 
        Phenotypic marker expression (Oct4, TRA-1-60, SSEA4);
      
- 
        Retention of normal karyotype; and
      
- 
        Maintenance of pluripotency.
      
      Since 2006, Corning has worked with Geron to develop synthetic surface 
      matrices to support the scalable manufacturing of stem cells and derived 
      differentiated cell types (e.g., cardiomyocytes). Synthetic growth 
      surfaces could replace the biological surface coatings that are widely 
      used today to grow and differentiate pluripotent stem cells and may 
      offer increased reproducibility, cost savings, and regulatory advantages.
    
    
      Laboratory products using specialized surfaces, such as the Synthemax 
      surface, are being commercialized by Corning. Currently, Corning’s 
      six-well plate with the Corning Synthemax surface is available in North 
      America.
    
    Source Corning Incorporated